High efficacy of a low dose candidate malaria vaccine, R21 in 1 adjuvant Matrix-M™, with seasonal administration to children in burkina faso

Abstract

A malaria vaccine candidate, R21/Matrix-M, was tested in a phase II trial in Burkina Faso against seasonal malaria transmission. The trial showed significantly high efficacy of the vaccine candidate, reaching the WHO-specified efficacy goal of ≥75% in the target population of African children. This novel pre-erythrocytic vaccine demonstrated very high immunogenicity in African children and appeared safe. – AI-generated abstract.